Pharmacokinetic (PK) studies for RXFP1-agonists

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98026Q00976. This solicitation is issued as a competitive combined synopsis/solicitation for commercial products or commercial services. The Government intends to award a contract or purchase order resulting from this solicitation using full and open competition. This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold (if applicable). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, seeks to award a (Firm-Fixed-Price) to the offeror responsible whose proposal represents the best value to the Government. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular effective August 7, 2026 (iv) The associated NAICS code is 541380 Testing Laboratories and Services, and the small business size standard is $19.0 million. This requirement is unrestricted.

• NAICS541380
• PSCR499

• Sol_75N98026Q00976.pdf

  .pdf565 KB
  Download

• JOHNSTON, JADDUA C
  jaddua.johnston@nih.gov+1 000 000 0000